Skip to main content

Advertisement

SpringerLink
Log in

Acceptability and effectiveness for withdrawal symptom relief of a novel oral nicotine delivery device: a randomised crossover trial

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Existing nicotine replacement therapies (NRT) improve the chances of smoking cessation but are limited by either relatively slow nicotine absorption rates or unpleasant side effects, leaving scope for the development of more effective and acceptable products.

Objectives

This study aimed to test the acceptability and effectiveness for withdrawal symptom relief of a novel nicotine delivery device, the ‘Nicotine Cannon’ (NC), compared with three existing, equivalent products: the nicotine lozenge, mini-lozenge and nicotine inhalator.

Methods

A repeated-measures crossover trial where participants were randomised to one of two conditions (1- or 10-h abstinence) and in each condition to one of 24 possible sequence permutations to test each product for 10 min was carried out. Standard sociodemographic and smoking characteristics were assessed as well as withdrawal and NRT use symptoms before, during and after NRT use and product satisfaction after use.

Results

The results were similar across both durations of abstinence. The NC was significantly more effective than the inhalator in reducing withdrawal symptoms (F(3, 196) = 3.5, p = 0.015) and together with the mini-lozenge performed better than other NRT in alleviating urges to smoke (F(3, 563) = 9.6, p < 0.001) and desire for cigarettes within 10 min of use (F(3, 727) = 26.1, p < 0.001). The NC induced fewer adverse side effects than other NRT and was judged to be more enjoyable (F(3, 87) = 13.56, p < 0.001) and satisfying to use (F(3, 92) = 12.35, p < 0.001).

Conclusions

The ‘Nicotine Cannon’ is at least as effective as equivalent NRT in reducing withdrawal symptoms and more acceptable to users, suggesting that it would be a useful addition to existing NRT. The acceptability profile could make it particularly useful as a ‘harm reduction’ tool.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Anthony J, Warner L, Kessler R (1994) Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharm 2:244–268

    Article  Google Scholar 

  • Beard E, McNeill A, Aveyard P, Fidler J, Michie S, West R (2011) Use of nicotine replacement therapy for smoking reduction and during enforced temporary abstinence: a national survey of English smokers. Addiction 106(1):197–204

    Google Scholar 

  • Bolliger CT, van Biljon X, Axelsson A (2007) A nicotine mouth spray for smoking cessation: a pilot study of preference, safety and efficacy. Respiration 74:196–201

    Article  PubMed  CAS  Google Scholar 

  • Bullen C, McRobbie H, Thornley S, Glover M, Lin R, Laugesen M (2010) Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob Control 19:98–103

    Article  PubMed  CAS  Google Scholar 

  • Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG (2007) Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav 32:912–923

    Article  PubMed  Google Scholar 

  • Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175–191

    Article  PubMed  Google Scholar 

  • Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A (1999) Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 159:2033–2038

    Article  PubMed  CAS  Google Scholar 

  • Heatherton TF, Kozlowski LT, Frecker RC, Rickert W, Robinson J (1989) Measuring the heaviness of smoking: using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. Br J Addict 84:791–799

    Article  PubMed  CAS  Google Scholar 

  • Jarvis MJ, Belcher M, Vesey C, Hutchison DC (1986) Low cost carbon monoxide monitors in smoking assessment. Thorax 41:886–887

    Article  PubMed  CAS  Google Scholar 

  • Krueger C, Tian L (2004) A comparison of the general linear mixed model and repeated measures ANOVA using a dataset with multiple missing data points. Biol Res Nurs 6:151–157

    Article  PubMed  Google Scholar 

  • McEwen A, West R, Gaiger M (2008) Nicotine absorption from seven current nicotine replacement products and a new wide-bore nicotine delivery device. J Smoking Cessation 3:117–123

    Google Scholar 

  • McRobbie H, Thornley S, Bullen C, Lin RB, Senior H, Laugesen M, Whittaker R, Hajek P (2010) A randomized trial of the effects of two novel nicotine replacement therapies on tobacco withdrawal symptoms and user satisfaction. Addiction 105:1290–1298

    Article  PubMed  Google Scholar 

  • MHRA (2010) MHRA Public Assessment Report: the use of nicotine replacement therapy to reduce harm in smokers. Medicine and Healthcare Products Regulatory Agency, London

    Google Scholar 

  • Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P (2009) Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 338:b1024

    Article  PubMed  Google Scholar 

  • Rose JE, Turner JE, Murugesan T, Behm FM, Laugesen M (2010) Pulmonary delivery of nicotine pyruvate: sensory and pharmacokinetic characteristics. Exp Clin Psychopharmacol 18:385–394

    Article  PubMed  CAS  Google Scholar 

  • Royal College of Physicians (2000) Nicotine addiction in Britain. A report of the Tobacco Advisory Group of the Royal College of Physicians. Royal College of Physicians of London, London

    Google Scholar 

  • Royal College of Physicians (2007) Harm reduction in nicotine addiction: helping people who can't quit. Royal College of Physicians of London, London

    Google Scholar 

  • Shahab L, West R (2010) Public support in England for a total ban on the sale of tobacco products. Tob Control 19:143–147

    Article  PubMed  Google Scholar 

  • Shiffman S, Cone EJ, Buchhalter AR, Henningfield JE, Rohay JM, Gitchell JG, Pinney JM, Chau T (2009) Rapid absorption of nicotine from new nicotine gum formulations. Pharmacol Biochem Behav 91:380–384

    Article  PubMed  CAS  Google Scholar 

  • Shiffman S, Ferguson SG, Gwaltney CJ, Balabanis MH, Shadel WG (2006) Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy. Psychopharmacology (Berl) 184:637–644

    Article  CAS  Google Scholar 

  • Shiffman S, Paty JA, Gnys M, Kassel JA, Hickcox M (1996) First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol 64:366–379

    Article  PubMed  CAS  Google Scholar 

  • Shiffman SM, Jarvik ME (1976) Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology (Berl) 50:35–39

    Article  CAS  Google Scholar 

  • Stead LF, Perera R, Bullen C, Mant D, Lancaster T (2008) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev CD000146

  • Sutherland G, Stapleton JA, Russell MA, Jarvis MJ, Hajek P, Belcher M, Feyerabend C (1992) Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 340:324–329

    Article  PubMed  CAS  Google Scholar 

  • Thornley S, McRobbie H, Lin RB, Bullen C, Hajek P, Laugesen M, Senior H, Whittaker R (2009) A single-blind, randomized, crossover trial of the effects of a nicotine pouch on the relief of tobacco withdrawal symptoms and user satisfaction. Nicotine Tob Res 11:715–721

    Article  PubMed  CAS  Google Scholar 

  • Watkins SS, Koob GF, Markou A (2000) Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2:19–37

    Article  PubMed  CAS  Google Scholar 

  • West R (2009) The multiple facets of cigarette addiction and what they mean for encouraging and helping smokers to stop. COPD 6:277–283

    Article  PubMed  Google Scholar 

  • West R, Hajek P (2004) Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. Psychopharmacology (Berl) 177:195–199

    Article  CAS  Google Scholar 

  • West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A (2000) A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl) 149:198–202

    Article  CAS  Google Scholar 

  • West R, Shiffman S (2007) Fast facts: smoking cessation. Health, Oxford

    Google Scholar 

  • West R, Ussher M, Evans M, Rashid M (2006) Assessing DSM-IV nicotine withdrawal symptoms: a comparison and evaluation of five different scales. Psychopharmacology (Berl) 184:619–627

    Article  CAS  Google Scholar 

  • WHO (1998) Action for tobacco control. In: Guideline for controlling and monitoring the tobacco epidemic. World Health Organization, Geneva

Download references

Acknowledgements

This study was funded by Cancer Research UK. We would like to thank Nick Wilson and Exchange Supplies for organising production of the ‘Nicotine Cannon’ and Jade Dyer and Antonia Shahab for their help with carrying out this study.

Conflicts of interest

Lion Shahab has received an honorarium for a talk and travel expenses from a pharmaceutical company making smoking cessation products (Pfizer). Andy McEwen (Pfizer, GSK, Novartis) and Robert West (Pfizer, J7J, McNeil, GSK, Nabi, Novartis, Sanofi-Aventis) have received travel funding, research grants, honoraria and consultancy payments from manufacturers of smoking cessation products. Robert West and Andy McEwen also have a share in the patent for the Nicotine Cannon.

Author information

Authors and Affiliations

  1. Cancer Research UK Health Behaviour Research Centre, Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London, WC1E 6BT, UK

    Lion Shahab, Andy McEwen & Robert West

Authors
  1. Lion Shahab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andy McEwen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert West
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lion Shahab.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shahab, L., McEwen, A. & West, R. Acceptability and effectiveness for withdrawal symptom relief of a novel oral nicotine delivery device: a randomised crossover trial. Psychopharmacology 216, 187–196 (2011). https://doi.org/10.1007/s00213-011-2204-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-011-2204-9

Keywords

Search

Navigation